Expression of CA125 in pancreatic carcinoma and chronic pancreatitis

Macdonald, Fiona; Downing, R.; Allum, William

doi:10.1038/bjc.1988.251

Cited by 16 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These authors detected MUC16 in 14%, 55%, and 91% of poorly, moderately, and well-differentiated tumors, respectively [25]. Their results contrast with ours, as we found a strong correlation between MUC16 expression and aggressive tumor features.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

et al. 2012

View full text Add to dashboard Cite

Summary Mucin 16 (cancer antigen 125) is a cell surface glycoprotein that plays a role in promoting cancer cell growth in ovarian cancer. The aims of this study were to examine mucin 16 expression in a large number of digestive tract adenocarcinomas and precursors and to determine whether mucin 16 up-regulation is correlated with patient outcome. Tissue microarrays were constructed using surgical resection tissues and included pancreatic (115 normal, 29 precursors, 200 pancreatic ductal adenocarcinomas), esophageal (86 normal, 104 precursors, 95 esophageal adenocarcinomas, 35 lymph node metastases), gastric (211 normal, 8 precursors, 119 gastric adenocarcinomas, 62 lymph node metastases), and colorectal (34 normal, 17 precursors, 39 colorectal adenocarcinomas) tissues. Mucin 16 was detected in 81.5%, 69.9%, 41.2%, and 64.1% of the pancreatic ductal adenocarcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, and colorectal adenocarcinomas, respectively. Mucin 16 was seen in a subset of the precursors. On multivariate analysis, moderate/diffuse mucin 16 in pancreatic ductal adenocarcinomas was strongly associated with poor survival (P < .001), independent of other prognosis predictors. A similar trend was observed for esophageal adenocarcinomas (P = .160) and gastric adenocarcinomas (P = .080). Focal mucin 16 in colorectal adenocarcinomas was significantly correlated (P = .044) with a better patient outcome, when compared with mucin 16–negative cases. Using Western blot analysis, we found mucin 16 expression in 3 of 6 pancreatic ductal adenocarcinoma and 1 of 2 esophageal adenocarcinoma cell lines. We conclude that most of the digestive tract adenocarcinomas and a subset of their precursors express mucin 16. Mucin 16 expression is an independent predictor of poor outcome in pancreatic ductal adenocarcinomas and potentially in esophageal adenocarcinomas and gastric adenocarcinomas. We propose that mucin 16 may function as a prognostic marker and therapeutic target in the future.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…In 1988, Macdonald et al [25] were the first to report immunolabeling for MUC16 in PDACs. These authors detected MUC16 in 14%, 55%, and 91% of poorly, moderately, and well-differentiated tumors, respectively [25].…”

Section: Discussionmentioning

confidence: 99%

Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

et al. 2012

View full text Add to dashboard Cite

show abstract

“…13, 15, 25]. Koelma et al [25] found C A 125 in 10% of carcinomas of the stomach, and in 4% of the colorectum; Macdonald et al [15] -in 59% of carcinomas of the pancreas. Thus, the demonstration of C A 125 in tumor tissue in the ovary is compatible with primary ovar ian tumor in most cases as well as with a metastasis from a primary in the breast or G I tract [2-4, 13, 15, 25], Serum levels of C A 125 are related to immunoperoxidase staining o f the malig nant cells.…”

Section: Discussionmentioning

confidence: 99%

Serum Levels of CA 125 in Patients with Gastrointestinal Cancers

Omar¹,

Al-Naqeeb²,

Nas³

et al. 1989

Tumor Biol

View full text Add to dashboard Cite

Serum levels of CA 125 and markers reputed as specific for cancers in relevant locations (squamous cell carcinoma, SCC, carcinoembryonic antigen, CEA, CA 19.9, α-fetoprotein, AFP) were determined in 107 patients with gastrointestinal (GI) carcinomas. The aim of this study was to assess their individual and combined sensitivities, and the power of CA 125 in excluding primary ovarian epithelial cancer from GI primary. Serum CA 125 levels (in U/ml) ranged from nondetectable to 400 in patients with esophageal, to 570 in those with gastric, and to 300 in patients with colorectal carcinoma. The levels for liver secondaries, pancreatic, and hepatocellular carcinoma were 480, 2,720 and 1,100 U/ml, respectively. Serum SCC antigen was elevated in all patients with esophageal cancer, CEA or CA 19.9 in 52% of patients with gastric cancer and in 63% with liver secondaries, and CEA in 95% of patients with colorectal cancer; whereas serum CA 125 above 65 U/ml was found in 25% of this subgroup, but only in those with already an elevated concentration of specific marker(s). Serum CEA or CA 19.9 was elevated in 71%, CA 125 in 59% of patients with pancreatic cancer; the latter mostly in those with already elevated CEA or CA 19.9. Serum AFP was elevated in 84% and CA 125 in 40% of patients with hepatoma; the latter mostly in those with already an elevated AFP. CA 125 values exceeding 1,000 U/ml were found in 1 patient with pancreatic cancer (2,720 U/ml) and in 2 with hepatoma (1,050 and 1 100 U/ml). These findings illustrate the nonspecificity of the CA 125 antigen, its small if any advantage compared to the specific markers, and they diminish its role as a marker for primary ovarian cancer from GI primary unless it exceeds 2,800 U/ml.

show abstract

“…In addition, an elevated CEA level can be found in a variety of cancers including colon cancers which indicates that such protein marker lack their lung-cancer specificity and may be a general cancer marker only [12,13]. CEA is also detected in other pathological conditions such as heart failure, hepatic cirrhosis and pancreatitis, which further complicate the interpretation of such markers when cancer patients simultaneously carry those diseases [14][15][16].…”

mentioning

confidence: 99%

Preoperative serum CA125 is an independent predictor for prognosis in operable patients with non-small cell lung cancer

Liu¹,

Wu²,

Zhang³

et al. 2015

neo

View full text Add to dashboard Cite

The role of serum CA125 and CEA in the prognosis of non-small cell lung cancer (NSCLC) remains controversial, especially in early stage patients, which need further clarification. Thus, in this study we carried out a large scale retrospective analysis of the prognostic value of CA125 and CEA in 645 patients with NSCLC, to explore their predictive value in the NSCLC. Patients who underwent curative surgical resection for NSCLC were from Zhejiang Cancer Hospital of China from 2006 to 2011. Microparticle enzyme immunoassay was used to measure preoperative serum CA125 and CEA. Univariate analyses and a multivariable proportional hazard Cox regression model were applied to assess the prognostic significance of the different covariates. Kaplan-Meier method was used to analyze survival curve. Both CA125 and CEA were correlated with stage, but also CA125 was different by grade, and CEA was related to histology. The Kaplan-Meier survival analysis showed that patients with elevated CA125 or CEA had unfavorable disease progression-free and overall survival time compared to those with normal CA125 or CEA. Furthermore, multivariate Cox analysis revealed that elevated CA125 had significantly higher risk for relapse (HR, 1.76; p=0.001) and death (HR, 1.80; p<0.001), but not for elevated CEA as relapse (HR, 1.06; p=0.736) and death (HR, 1.25; p= 0.119) both were statistically non significant. This study showed that both CA125 and CEA play important roles in disease progression while only CA125 as an independent predictive marker for prognosis in patients with NSCLC.

show abstract

Expression of CA125 in pancreatic carcinoma and chronic pancreatitis

Cited by 16 publications

References 7 publications

Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

Serum Levels of CA 125 in Patients with Gastrointestinal Cancers

Preoperative serum CA125 is an independent predictor for prognosis in operable patients with non-small cell lung cancer

Contact Info

Product

Resources

About